Advagene Biopharma , Ltd. Return on Equity

Advagene Biopharma , Ltd. (6709.TWO) currently reports a ROE of -45.49%. That is above the Healthcare sector average of -100.59%. Use the charts on this page to explore Advagene Biopharma , Ltd.'s ROE history and peer comparisons.

Advagene Biopharma , Ltd.'s ROE of -45.49% is higher than the Healthcare sector average of -100.59%. That is roughly 54.8% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Advagene Biopharma , Ltd.'s current -45.49% should be judged against Healthcare norms (sector average: -100.59%) and against 6709.TWO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -45.49%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -100.59%. From there, open related valuation or income-statement pages for Advagene Biopharma , Ltd., and consider following 6709.TWO for alerts when major investors trade the stock.

Advagene Biopharma , Ltd. is classified in the Healthcare sector. On ROE, it currently shows -45.49% versus a sector average near -100.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 6709.TWO with unrelated industries.